Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss discussion includes PRP and exosomes treatments. Questioning effectiveness and ideal candidate for these treatments.

User experienced hair loss since 16, used Fin, Minox, and Nizoral with success but stopped due to side effects. Now using Pur D'or shampoo, Rogaine foam, scalp massages, volumizing spray, and dermarolling for hair maintenance.

The conversation discusses diffuse unpatterned alopecia (DUPA) and its possible causes, including sensitivity to DHT, not being androgenic alopecia, being diffuse alopecia areata, or hormonal issues. Treatments mentioned include topical melatonin, Clobetasol Propionate for alopecia areata, and the lack of results from using finasteride, dutasteride, and minoxidil.

Mixing ketoconazole 2% shampoo with coal tar and salicylic acid for seborrheic dermatitis is discussed, with users sharing experiences and alternative treatments like sulfur soap and scalp massage. Some users report success with these methods, emphasizing the importance of avoiding irritants and maintaining scalp health.

A user with alopecia totalis, borderline universalis, seeks advice on getting into a Xeljanz trial or appealing insurance for coverage. They experienced significant hair regrowth but are now seeing hair loss again and want to try Xeljanz.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

The user shared their hair loss treatment progress using minoxidil, ketoconazole shampoo, a dermaroller, biotin, Pura d'or shampoo, and Propidren. They apply minoxidil daily, take Propidren and biotin pills, use two types of shampoo, and use a dermaroller weekly, avoiding finasteride due to concerns about side effects.

A user is experiencing significant hair loss and scalp issues despite using Minoxidil, finasteride, and RU58841 since 2017. They switched to oral Minoxidil and are now on isotretinoin and topical corticosteroids for seborrheic dermatitis but continue to lose hair and seek advice on whether inflammation or treatment changes are the cause.

Male pattern baldness (MPB) may be influenced by androgen receptors in scalp hair follicles and potentially poor blood flow. Transplanted hair is not immune to DHT, and factors like inflammation and scalp tension might also contribute to hair loss.

Balding scalps have more androgen receptors, leading to increased TGF-beta, which causes blood vessel loss and hair follicle miniaturization. Blocking androgen signaling and TGF-beta may help prevent hair loss.

A user noticed non-itchy, non-bleeding spots on their scalp while experiencing hair loss. Replies suggest the spots are likely sunspots or liver spots and recommend seeing a dermatologist; hair loss is attributed to male pattern baldness.

David Barreto shared that a London-based research group is conducting a 12-month trial for a new nutraceutical treatment for pattern hair loss, designed with Dr. Carlos Puig. The trial aims to provide robust data, with results expected in 1-2 years, potentially representing a significant advancement since finasteride’s introduction in 1997.

The user has been using dutasteride, lymecycline, betamethasone, and minoxidil for hair loss but struggles with eczema and dry skin. They feel hopeless as no treatments or moisturizers have helped, and they are concerned about their appearance due to their soft facial features.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

The conversation discusses the effects of B5 (Pantothenic acid), B7 (Biotin), and B12 on hair loss. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Male pattern baldness can occur with or without an oily scalp, but an oily scalp and seborrheic dermatitis can worsen the condition. Treatments like finasteride, minoxidil, and ketoconazole shampoo are used, and managing diet and scalp care can help control symptoms.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

The user noticed hair thinning since age 15, initially attributed to a Vitamin D deficiency. They are currently using Rogaine and considering Propecia but are hesitant about a scalp biopsy; they seek financially practical treatments for male-pattern baldness.

A user is experiencing severe hair loss, diagnosed with seborrheic dermatitis, and is using Ketoconazole and beclomethasone. They are concerned about potential female pattern baldness and are seeking reassurance and advice.

After suffering from hair loss and Seborrheic Dermatitis for three years with no improvement from various treatments, the individual found success with COQ10 and PQQ supplements, which led to new hair growth and a healthy scalp without flare-ups. They also plan to start additional supplements recommended by a dermatologist.

The user experienced hair loss since 2019 and tried finasteride, dutasteride, RU58841, and ketoconazole shampoo without success. A scalp biopsy showed scarring and inflammation from folliculitis, indicating chronic inflammation was affecting treatment effectiveness.

Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.

The conversation discusses hair loss treatments, specifically Setipiprant, finasteride, and bimatoprost. Setipiprant is suggested for maintenance, while bimatoprost is for regrowth, and combining them with dermarolling is recommended for better results.

A gel of keratin microspheres promotes hair follicle growth, showing similar effectiveness to minoxidil in mice. The treatment activates hair growth pathways and reduces inflammation, with potential applications in drug delivery for hair-related disorders.

Latanoprost is discussed as a potential hair loss treatment, noted for its synergy with minoxidil and 5-AR inhibitors, but concerns include its effectiveness on scalp hair, cost, and potential skin darkening. Some users express interest in trying latanoprost or bimatoprost despite limited real-world evidence.

A user shared their positive experience with scalp micropigmentation (SMP) to cover hair thinning and a scar, choosing it over hair transplants due to its non-invasive nature and realistic results. They recommend SMP for those struggling with hair loss, emphasizing the importance of finding a trusted artist.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

User is experiencing increased sebum, dandruff, and acne after taking a supplement containing biotin, iron, zinc, and calcium pantothenate along with finasteride. They are questioning if biotin is the cause and whether they should stop taking it.

A person with hair loss due to seborrheic dermatitis saw improvement after treating the condition and using 5mg oral minoxidil, topical minoxidil, collagen, biotin, and vitamins. They are asking if the progress is real, and others have noted the oral minoxidil as a significant treatment.